Authors

Bridget Freisthler, Ohio State UniversityFollow
Rouba A. Chahine, RTI International
Jennifer Villani, National Institutes of Health
Redonna Chandler, National Institutes of Health
Daniel J. Feaster, University of Miami
Svetla Slavova, University of KentuckyFollow
Jolene Defiore-Hyrmer, State of Ohio Board of Pharmacy
Alexander Y. Walley, Boston Medical Center
Sarah Kosakowski, Boston Medical Center
Arnie Aldridge, RTI International
Carolina Barbosa, RTI International
Sabana Bhatta, New York State Department of Health
Candace Brancato, University of KentuckyFollow
Carly Bridden, Boston Medical Center
Mia Christopher, RTI International
Tom Clarke, Substance Abuse and Mental Health Services Administration
James David, Columbia University
Lauren D'Costa, RTI International
Irene Ewing, University of Cincinnati
Soledad Fernandez, Ohio State University
Erin Gibson, Boston Medical Center
Louisa Gilbert, Columbia University
Megan E. Hall, RTI International
Sarah Hargrove, University of Kentucky
Timothy Hunt, Columbia University
Elizabeth N. Kinnard, Boston Medical Center
Lauren Larochelle, Massachusetts Department of Public Health
Aaron Macoubray, RTI International
Shawn R. Nigam, University of KentuckyFollow
Edward V. Nunes, Columbia University Irving Medical Center
Carrie B. Oser, University of KentuckyFollow
Sharon Pagnano, Massachusetts Department of Public Health
Peter J. Rock, University of KentuckyFollow
Pamela Salsberry, Ohio State University
Aimee Shadwick, Recovery Ohio
Thomas J. Stopka, Tufts University
Sylvia Tan, RTI International
Jessica L. Taylor, Boston Medical Center
Philip M. Westgate, University of KentuckyFollow
Elwin Wu, Columbia University
Gary A. Zarkin, RTI International
Sharon L. Walsh, University of KentuckyFollow
Nabila El-Bassel, Columbia University
T. John Winhusen, University of Cincinnati
Jeffrey H. Samet, Boston Medical Center
Emmanuel A. Oga, RTI International

Abstract

IMPORTANCE: The HEALing Communities Study (HCS) evaluated the effectiveness of the Communities That HEAL (CTH) intervention in preventing fatal overdoses amidst the US opioid epidemic.

OBJECTIVE: To evaluate the impact of the CTH intervention on total drug overdose deaths and overdose deaths involving combinations of opioids with psychostimulants or benzodiazepines.

DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a parallel-arm, multisite, community-randomized, open, and waitlisted controlled comparison trial of communities in 4 US states between 2020 and 2023. Eligible communities were those reporting high opioid overdose fatality rates in Kentucky, Massachusetts, New York, and Ohio. Covariate constrained randomization stratified by state allocated communities to the intervention or control group. Trial groups were balanced by urban or rural classification, 2016-2017 fatal opioid overdose rate, and community population. Data analysis was completed by December 2023.

INTERVENTION: Increased overdose education and naloxone distribution, treatment with medications for opioid use disorder, safer opioid prescribing practices, and communication campaigns to mitigate stigma and drive demand for evidence-based interventions.

MAIN OUTCOMES AND MEASURES: The primary outcome was the number of drug overdose deaths among adults (aged 18 years or older), with secondary outcomes of overdose deaths involving specific opioid-involved drug combinations from death certificates. Rates of overdose deaths per 100 000 adult community residents in intervention and control communities from July 2021 to June 2022 were compared with analyses performed in 2023.

RESULTS: In 67 participating communities (34 in the intervention group, 33 in the control group) and including 8 211 506 participants (4 251 903 female [51.8%]; 1 273 394 Black [15.5%], 603 983 Hispanic [7.4%], 5 979 602 White [72.8%], 354 527 other [4.3%]), the average rate of overdose deaths involving all substances was 57.6 per 100 000 population in the intervention group and 61.2 per 100 000 population in the control group. This was not a statistically significant difference (adjusted rate ratio [aRR], 0.92; 95% CI, 0.78-1.07; P = .26). There was a statistically significant 37% reduction (aRR, 0.63; 95% CI, 0.44-0.91; P = .02) in death rates involving an opioid and psychostimulants (other than cocaine), and nonsignificant reductions in overdose deaths for an opioid with cocaine (6%) and an opioid with benzodiazepine (1%).

CONCLUSION AND RELEVANCE: In this clinical trial of the CTH intervention, death rates involving an opioid and noncocaine psychostimulant were reduced; total deaths did not differ statistically. Community-focused data-driven interventions that scale up evidence-based practices with communications campaigns may effectively reduce some opioid-involved polysubstance overdose deaths.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04111939.

Document Type

Article

Publication Date

10-1-2024

Notes/Citation Information

This is an open access article distributed under the terms of the CC-BY License. © 2024 Freisthler B et al. JAMA Network Open.

Digital Object Identifier (DOI)

https://doi.org/10.1001/jamanetworkopen.2024.40006

Funding Information

This research was supported by the National Institutes of Health and the Substance Abuse and Mental Health Services Administration through the NIH HEAL (Helping to End Addiction Long-term) Initiative under award numbers UM1DA049394, UM1DA049406, UM1DA049412, UM1DA049415, UM1DA049417. Drs Villani and Chandler were substantially involved in grants (Nos. UM1DA049394, UM1DA049406, UM1DA049412, UM1DA049415, and UM1DA049417) consistent with their role as scientific officers.

Share

COinS